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Large retrospective databases provide valuable information to examine adverse events 
associated with PN, which can be reliably identiﬁed and studied. Both sensitivity analy-
ses and model validation added credibility to our approach.
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OBJECTIVES: National asthma treatment guidelines recommend the use of low dose 
ICS plus a LABA or moderate to high dose ICS as the preferred treatment for moderate 
asthma. The purpose of this study was to determine if physicians prescribe low/moder-
ate dose ﬂuticasone propionate/salmeterol (FSC) or moderate/high dose ﬂuticasone 
propionate (FP) to subjects with similar asthma clinical proﬁles, medication use, and 
symptomology. METHODS: This was a retrospective observational study using 
medical, pharmacy, and enrollment information from a large, US managed care plan 
and linked medical chart data comparing 3 years of baseline characteristics and medi-
cation treatment patterns in adult asthma patients initiating FSC or FP. Data acquired 
from medical and pharmacy claims included provider specialty, baseline asthma medi-
cation resource use, occurrence of spirometry testing, and Deyo-Charlson co-morbid-
ity score. A random sample of medical charts (n = 460) was abstracted for baseline 
symptomology. RESULTS: A total of 32,189 subjects (average age: 46.6 [±14.4] years; 
64% female) with an asthma diagnosis and initiating FSC or FP were identiﬁed from 
1/1/06-12/31/07. Baseline co-morbidity scores were similar in FSC and FP patients 
(1.02 (1.31)) vs. 1.11 (1.50); p = 0.488). A greater proportion of patients receiving 
FSC had a baseline spirometry compared to FP patients (32.6% vs. 20.4%; p = 0.003) 
while. Shortness of breath was reported signiﬁcantly more often for FSC (48.7% in 
FSC vs 38.3% in FP; p = 0.024). Other asthma symptoms were reported a similar rate 
across both groups and no signiﬁcant differences in baseline use of other asthma 
medications were observed. CONCLUSIONS: Few signiﬁcant differences in either 
claims history or asthma symptomology were observed between patients prescribed 
low/moderate dose FSC or moderate/high dose FP for the ﬁrst time. Overall, physicians 
seem to be prescribing low/moderate dose FSC and moderate/high dose FP to similar 
asthma patients in alignment with national asthma treatment guidelines.
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OBJECTIVES: In most studies, the inﬂuence of comorbidity is modelled additively as 
the number of comorbidities present or by an index (such as Charlson’s) chosen 
without regard to the outcome of interest. We question these approaches with a novel 
methodology noting that: outcome may not be associated linearly with comorbidity 
count, the weights combining a set of binary comorbidities need not be positive (i.e. 
hypothesis (B) that outcome worsens with increasing comorbidity may be false), and 
our ability to identify speciﬁc interactions inﬂuencing prognosis is lost METHODS: 
We analyzed a retrospective cohort of 3332 patients, aged 50+ in the UK General 
Practice Research Database diagnosed with COPD between 1990 and 1998, and with 
a ﬁrst COPD hospitalisation. Some 17 binary comorbidities were analysed in relation 
to risk of mortality and re-hospitalisation. We tested the null hypothesis (A), that 
comorbidity was similar in each layer of the two outcomes, crudely and adjusting for 
age and sex. Our methodology relies on logistic and log-linear modelling strategies 
for multidimensional contingency tables RESULTS: For both outcomes, hypothesis 
(A) was rejected (p < 0.001). Although comorbidity was found to inﬂuence death and 
rehospitalisation, the patterns of inﬂuence on the two outcomes were not similar and 
there were some with negative inﬂuence (i.e. comorbidities more frequent among 
survivors or those not rehospitalised); several signiﬁcant 2-way interactions were 
revealed. Whilst most signiﬁcant interactions were positive (especially for re-hospital-
isation) there was negative interaction for death (e.g. peripheral vascular disease and 
CVD were more frequent among survivors), thus rejecting hypothesis (B) CONCLU-
SIONS: The use of these modelling approaches, in addition to or in place of existing 
comorbidity indices, will improve our understanding of how comorbidity relates to 
disease natural history and outcomes of interest. The application of this method to 
understanding potential high risk patient strata in beneﬁt/risk management planning 
is particularly appealing
PRS3
THE PREVALENCE OF COMORBID CONDITIONS IN U.S. PATIENTS 
DIAGNOSED WITH CHRONIC OBSTRUCTIVE PULMONARY  
DISEASE (COPD)
Hess G
SDI / Leonard Davis Inst University of Penn, Plymouth Meeting, PA, USA
OBJECTIVES: COPD is the 4th leading cause of death among U.S. adults. Retrospec-
tive observational studies, including outcomes research, can provide important com-
parative analyses to help identify optimal treatment patterns and therapies. However, 
such comparisons often require multivariate analysis, propensity score matching, a 
comorbidity index or other methods to adjust for differences in patient characteristics. 
Rates reported in clinical trials often vary signiﬁcantly from those observed in clinical 
practice. Using recent, real-world data this study was designed to identify the fre-
quency of diagnosed comorbid conditions in the COPD population and serve as a 
research reference for future comparative studies. METHODS: Private practitioner 
medical claims (CMS1500 records) from SDI Health’s data warehouse were extracted 
for the period November 1, 2007 to October 21, 2008. Patients were indexed to their 
ﬁrst observed COPD diagnosis during the study period. Qualifying patients had 2 or 
more claims for COPD; a valid age and gender; and were observed in the dataset for 
12 months or more from their index date. Patients could be diagnosed with COPD 
prior to the study period or new to the condition. Comorbid conditions of interest 
were deﬁned a priori. As possible, MEDRA codes used in clinical trials were cross-
walked to corresponding ICD-9 codes. All payer types were included. RESULTS: Of 
the 751,794 qualifying study patients, the mean age was 67.5 years (STD+/−13) and 
55.4% were female. The 1 year prevalence of comorbid conditions observed was: 
Supraventricular Arrhythmia13.2%, Atrial Fibrillation 9.7%, Depression 9.0%, 
Suicide 0.1%, Insomnia 4.1%, Ischemic disease (ATPC composite) 28.8%, Metabolic 
Syndrome 0.4%, and Other Mental Health conditions 14.7%. CONCLUSIONS: 
Patients with COPD have a variety of signiﬁcant comorbid conditions observed in 
real-world, clinical practice. These factors can affect ﬁndings of comparative studies 
and are important considerations for future research.
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OBJECTIVES: Even in late-phase trials, it is common practice to exclude patients with 
certain pre-existing conditions based primarily on clinical knowledge. Such exclusions 
can result in low recruitment and associated consequences. Comorbidities are common 
in chronic diseases and for a speciﬁc outcome, data on the risk attributable to each 
can help inform decisions on inclusion/exclusion. We present a graphical methodology 
for obtaining such empirical evidence METHODS: A retrospective cohort of 23,881 
patients aged 50+ in the UK-GPRD at incident COPD diagnosis between 1990–1998 
provided our setting. Each death patient was matched to as many survivors from the 
same practice as possible, of same age, sex and COPD duration. Some 18 binary 
comorbidities measured at the time of death were analysed in relation to mortality. 
Using conditional logistic regression model, we estimated hazard ratio (HR) for each 
comorbidity, adjusted for key baseline characteristics as well as its prevalence at the 
time of COPD diagnosis (PRC) and in 1998 (PR98). We plotted the HRs against the 
PRCs and PR98s as graphs A and B respectively RESULTS: Some 2,938 dead patients 
were matched to 5792 survivors. The most contributors to mortality risk were- 
CHF (HR: 3.3 p < 0.0001; PRC = 15.6%, PR98 = 18.2%), lung cancer (HR: 20.4 
p < 0.0001; PRC = 0.7%, PR98 = 1.2%), other cancers (HR: 12.3 p < 0.0001; PRC 
= 0.7%, PR98 = 1.8%), and CVD (HR: 4.1 p < 0.0001; PRC = 3.2%, PR98 = 4.7%). 
Newly diagnosed moderate/severe liver disease (<1 year) was rare but with a high risk 
(HR: 16.7 p = 0.014; PRC = 0.3%, PR98 = 0.4%), suggesting such patients could be 
excluded in a trial. In contrast, diabetes-without-complication was common but with 
little effect on risk (HR: 1.2 p > 0.37; PRC = 5.1%, PR98 = 7.2%), suggesting such 
patients could be included in a trial with recruitment concerns CONCLUSIONS: The 
information provided by the tool can assist trial planning on sample size estimations 
as well as improve our understanding of how comorbidities inﬂuence outcome
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OBJECTIVES: To examine characteristics of demographic, clinical conditions, comor-
bidities, quality-of-life and health care access by risk cohorts calculated using Fram-
ingham risk percent in a United States (US) national sample. METHODS: 
Characteristics of 3 cohorts were deﬁned by Framingham low risk (<10%), middle 
risk (10%~20%) and high risk (>20%) and compared by mean and proportions of 
respondents using 2005–2006 National Health and Nutrition Examination Survey 
(NHNES) data. RESULTS: The sample comprised 1,751 persons aged ≥20 years with 
all necessary analysis variables (age, total cholesterol, smoking status, HDL, systolic 
blood pressure, and hypertension treatment) used to calculate Framingham 10-year 
risk percent. Compared to respondents in low and middle risk cohorts, the high risk 
cohort was older (61 years old vs. 42 and 60), more male (92% vs. 45% and 84%), 
and reported less years of education, less married (71% vs. 32% and 32%), more 
smokers (57% vs. 49% and 52%), higher levels of hypertension treatment (64% vs. 
19% and 51%) and a higher proportion of overweight and obese (76% vs. 61% and 
72%). More high risk cohort people reported diagnoses of hypertension (60% vs. 
24% and 45%), diabetes (15% vs. 5% and 11%), asthma (47% vs. 32% and 41%), 
and cancer (15% vs. 7% and 13%). Less of the high risk cohort reported “good 
health” conditions than those in low and middle risk cohorts (70% vs. 84% and 80%). 
The high risk cohort was more likely to report public insurance (54%) than either 
low (18%) or middle risk (46%) cohorts. CONCLUSIONS: An NHANES-based 
